In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ipsen, Tercica cross-license endocrine compounds

Executive Summary

In a 15-year deal, French pharma giant Ipsen and Tercica (therapeutics for metabolic disorders) are cross-licensing two products: Ipsen's Somatuline Autogel sustained-release injectable lanreotide for acromegaly and Tercica's Increlex mecasermin injection for growth failure in children.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies